Hypopigmentation is characterized by patches of skin that are lighter in color than the surrounding skin
These requirements mirror those that may have limited adoption of Rybelsus, the oral semaglutide from Novo Nordisk approved for diabetes in 2019. One challenge in developing oral versions of semaglutide is that the drug is based on chains of amino acids known as peptides which are subject to degradation by enzymes in the stomach. In contrast, Eli Lillys upcoming oral GLP1 candidate, orforglipron, is a smallmolecule drug rather than a peptide, which could lessen the need for dosing requirements and offer greater convenience to users. This ease of use has fueled expectations of growing market share for oral GLP-1 formulations, with analysts estimating they could generate $22 billion annually by 2030, capturing 24% of the global weight loss market. For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies
Chng ti vn cn nhiu nghin cu hn h tr hiu qu ca n cng nh nhiu cng ty bo him sn sng chi tr cho n, Tin s Gina Posner, mt bc s nhi khoa c hi ng chng nhn ti Trung tm Y t MemorialCare Orange Coast Fountain Valley, CA, ni vi Healthline
The scientists also found a variant of a different GIPR gene that was common in people who reported those side effects, when taking tirzepatide drugs
